Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors
Shots:
- Genentech to acquire Jecure- in all stock transaction for the portfolio of preclinical NLRP3 inhibitors
- The acquisition is focus to develop therapies using Jecure’s NLRP3 inhibitors for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis
- NLRP3 - Nucleotide-binding oligomerization (NOD)-like Receptor Family Pyrin Domain Containing Protein3- investigated for the treatment of autoimmune and inflammatory disorders
Ref: Jecure Therapeutics | Image: Xconomy
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com